ClinicalTrials.gg
RecruitingNCT04627870Updated Aug 1, 2024

ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis

An interventional study of drug (paclitaxel) coated balloon and PTA balloon in Intracranial Atherosclerosis and Stroke, sponsored by Acotec Scientific Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.

Planned enrollment
25th of 27
20 · median 200
Started
2021
with 4 others
No phase
16 of 44
8 open now
Primary completion
2024-12
later than 4 of 27 live
Registered
12th of 44
by date
Lead sponsor
2 of 44
Acotec Scientific Co., Ltd

Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 25th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 16 with no phase, reaches primary completion later than 4 of the 27 other live ones, and was the 12th registered.

Intracranial Arteriosclerosis

103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Open to participants now

28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Intracranial Arteriosclerosis with a site in China, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and feasibility of drug coated balloon in treatment of intracranial in-stent restenosis.

Read the detailed description

This study is a prospective, multi-center, randomized controlled trial using drug coated balloon versus uncoated PTA balloon in treatment of intracranial in-stent restenosis.

03

Conditions studied

  • Intracranial Atherosclerosis
  • Stroke

Keywords

  • Intracranial Atherosclerosis
  • In-stent restenosis
  • drug coated balloon
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years of age
  • Confirmed by DSA: in-stent restenosis (ISR) at intracranial segment of internal carotid artery, middle cerebral artery, basilar artery and vertebral artery; ISR is defined as >50% stenosis within or immediately adjacent (within 5 mm) of the implanted stent and >20% absolute luminal loss
  • presence of ISR associated ischemic stroke or even with medical treatment and strict control of risk factor
  • asymptomatic ISR with severe hypoperfusion in the ISR territories, confirmed by a cerebral blood flow decrease of ≥30% when compared with the perfusion on the contralateral side for anterior circulation lesions or the anterior circulation territory for posterior circulation lesions on CT perfusion, and/or by an American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) Collateral Flow Grading System score \<3 on DSA.
  • the diameter of target vessel is 2.0-4.5mm
  • there is only one intracranial ISR lesion per subject
  • baseline mRS score ≤2
  • Voluntarily participate in this study and sign the form

Exclusion criteria

Exclusion Criteria:

  • Patients with stroke within 2 weeks before procedure;
  • any history of brain parenchyma or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days.
  • Those who have received thrombolysis within 24 hours before procedure;
  • Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline)
  • patients with thrombus in target vessels.
  • in addition to ISR lesions, there are other primary intracranial lesions that need endovascular treatment.
  • Major surgery (including open femoral, aortic or carotid artery surgery) is planned within the past 30 days or within 90 days.
  • patients with renal artery, iliac artery and cardiac coronary artery requiring simultaneous intervention.
  • Combined with intracranial tumors, aneurysms or intracranial arteriovenous malformations.
  • Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;
  • patients with myocardial infarction within 6 weeks before procedure.
  • those who cannot tolerate general anesthesia due to insufficiency of heart, lung and other important organs.
  • patients with known severe hepatic and renal dysfunction.
  • patients with \< 100g / L, count \< 100,000 / mm3, > 1.5or with uncorrectable factors leading to bleeding.
  • patients who cannot receive dual antiplatelet therapy due to existing diseases or who are tested to be tolerant to dual antiplatelet therapy.
  • Patients with known severe allergies or to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs
  • current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure > 180mmHg or diastolic blood pressure > 110mmHg).
  • \< 1 year.
  • pregnant or lactating women.
  • patients who are unable to complete follow-up due to cognitive, emotional disorders or mental illness.
  • Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programme;
  • According to the judgement of the investigator, other situations that are not suitable for enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    DCB group

    use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis

    Device: drug (paclitaxel) coated balloon

  • Active comparator
    PTA group

    use PTA balloon to treat intracranial in-stent restenosis

    Device: PTA balloon

Interventions

  • Devicedrug (paclitaxel) coated balloon

    use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis

  • DevicePTA balloon

    use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis

06

What researchers measure

Primary outcomes

  1. Target vessel stroke or death event

    Target-vessel related stroke (bleeding and ischemia) or death within 30 days postoperatively.

    Time frame: within 30 days post-procedure

Secondary outcomes

  1. device success rate

    The balloon dilatation catheter was able to reach the treated lesion, successfully dilated without rupture, and successfully retreated.

    Time frame: assessed during procedure

  2. target vessel ischemia stroke event

    The incidence of recurrent ischemic stroke in the target vessel supply area 31 days to 12 months after surgery

    Time frame: between 31days and 12months post-procedure

  3. Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events

    Any cerebral parenchyma hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage confirmed by MRI or CT from 31 days to 12 months post procedure

    Time frame: between 31 days and 12 months post-procedure

  4. target vessel death event

    Target-vessel related death 31 days to 12 months postoperatively

    Time frame: between 31 days and 12 months post-procedure

  5. National Institutes of Health Stroke Scale score

    National Institutes of Health Stroke Scale score at 12 months postoperatively(0-42, higher scores mean a worse outcome)

    Time frame: at 12 months post-procedure

  6. Modified Rankin Score score

    Modified Rankin Score at 12 months postoperatively(0-5, higher scores mean a worse outcome)

    Time frame: at 12 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Dec 2024, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 13, 2020
StartActual
May 26, 2021
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2025
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04627870
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
Nov 13, 2020
Start date
May 26, 2021
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Aug 1, 2024

Study contacts

Ning Ma, MD
Contact
maning_03@hotmail.com
010-59978585
Ning Ma, MD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion